JP2020500540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500540A5 JP2020500540A5 JP2019530735A JP2019530735A JP2020500540A5 JP 2020500540 A5 JP2020500540 A5 JP 2020500540A5 JP 2019530735 A JP2019530735 A JP 2019530735A JP 2019530735 A JP2019530735 A JP 2019530735A JP 2020500540 A5 JP2020500540 A5 JP 2020500540A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amino acid
- acid sequence
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 138
- 210000004027 cell Anatomy 0.000 claims 90
- 206010028980 Neoplasm Diseases 0.000 claims 69
- 238000006467 substitution reaction Methods 0.000 claims 39
- 230000000381 tumorigenic effect Effects 0.000 claims 34
- 210000001185 bone marrow Anatomy 0.000 claims 33
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 32
- 210000000440 neutrophil Anatomy 0.000 claims 30
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 28
- 210000000822 natural killer cell Anatomy 0.000 claims 27
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 23
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 23
- -1 ICOS Proteins 0.000 claims 20
- 210000000066 myeloid cell Anatomy 0.000 claims 20
- 210000004443 dendritic cell Anatomy 0.000 claims 18
- 239000000556 agonist Substances 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 210000000274 microglia Anatomy 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 13
- 210000002540 macrophage Anatomy 0.000 claims 12
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 11
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 11
- 238000002560 therapeutic procedure Methods 0.000 claims 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 10
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 230000003247 decreasing effect Effects 0.000 claims 9
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 8
- 102100038078 CD276 antigen Human genes 0.000 claims 8
- 101710185679 CD276 antigen Proteins 0.000 claims 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 8
- 101150036449 SIRPA gene Proteins 0.000 claims 8
- 238000009169 immunotherapy Methods 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 7
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 7
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 7
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 7
- 102000017578 LAG3 Human genes 0.000 claims 7
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 7
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 7
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 7
- 230000002147 killing effect Effects 0.000 claims 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 6
- 210000003690 classically activated macrophage Anatomy 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102100022464 5'-nucleotidase Human genes 0.000 claims 5
- 102100027207 CD27 antigen Human genes 0.000 claims 5
- 101150013553 CD40 gene Proteins 0.000 claims 5
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 5
- 102100031351 Galectin-9 Human genes 0.000 claims 5
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 5
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 5
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 5
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 5
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 5
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims 5
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims 5
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 5
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 5
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 5
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 5
- 108010043610 KIR Receptors Proteins 0.000 claims 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 5
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 5
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 5
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 5
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 5
- 230000000259 anti-tumor effect Effects 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 230000001413 cellular effect Effects 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 230000002519 immonomodulatory effect Effects 0.000 claims 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 5
- 230000008595 infiltration Effects 0.000 claims 5
- 238000001764 infiltration Methods 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 210000002084 suppressor macrophage Anatomy 0.000 claims 5
- 230000004083 survival effect Effects 0.000 claims 5
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 4
- 102000002698 KIR Receptors Human genes 0.000 claims 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 4
- 210000003714 granulocyte Anatomy 0.000 claims 4
- 102000049963 human SIRPA Human genes 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 210000005259 peripheral blood Anatomy 0.000 claims 4
- 239000011886 peripheral blood Substances 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 210000003289 regulatory T cell Anatomy 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 108700012359 toxins Proteins 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims 3
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 3
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 3
- 102100034980 ICOS ligand Human genes 0.000 claims 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 3
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 3
- 210000004322 M2 macrophage Anatomy 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 238000013508 migration Methods 0.000 claims 3
- 210000002997 osteoclast Anatomy 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 230000003252 repetitive effect Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 claims 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 claims 2
- 108010066676 Abrin Proteins 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 102000007372 Ataxin-1 Human genes 0.000 claims 2
- 108010032963 Ataxin-1 Proteins 0.000 claims 2
- 102000002785 Ataxin-10 Human genes 0.000 claims 2
- 108010043914 Ataxin-10 Proteins 0.000 claims 2
- 102000007371 Ataxin-3 Human genes 0.000 claims 2
- 108010032947 Ataxin-3 Proteins 0.000 claims 2
- 102000007368 Ataxin-7 Human genes 0.000 claims 2
- 108010032953 Ataxin-7 Proteins 0.000 claims 2
- 101710147490 Ataxin-8 Proteins 0.000 claims 2
- 102100026565 Ataxin-8 Human genes 0.000 claims 2
- 102000007370 Ataxin2 Human genes 0.000 claims 2
- 108010032951 Ataxin2 Proteins 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 108700030955 C9orf72 Proteins 0.000 claims 2
- 101150014718 C9orf72 gene Proteins 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000015833 Cystatin Human genes 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 102400001156 Medin Human genes 0.000 claims 2
- 101800003015 Medin Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 108010057464 Prolactin Proteins 0.000 claims 2
- 102000003946 Prolactin Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 2
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims 2
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- 102000054727 Serum Amyloid A Human genes 0.000 claims 2
- 108700028909 Serum Amyloid A Proteins 0.000 claims 2
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 2
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 108090000848 Ubiquitin Proteins 0.000 claims 2
- 102000044159 Ubiquitin Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 229940009456 adriamycin Drugs 0.000 claims 2
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 230000001746 atrial effect Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 229960004015 calcitonin Drugs 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 238000009566 cancer vaccine Methods 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 108050004038 cystatin Proteins 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940087477 ellence Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000009545 invasion Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000005210 lymphoid organ Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 229940097325 prolactin Drugs 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 230000000722 protumoral effect Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 101710155855 C-C motif chemokine 4 Proteins 0.000 claims 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 claims 1
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 102100036721 Insulin receptor Human genes 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 241000219287 Saponaria Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 claims 1
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000002788 anti-peptide Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
- GBVKRUOMSUTVPW-AHNVSIPUSA-N chembl1089636 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)N[C@@H](C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 GBVKRUOMSUTVPW-AHNVSIPUSA-N 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 108010028531 enomycin Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims 1
- 229960005542 ethidium bromide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 210000005008 immunosuppressive cell Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108091008042 inhibitory receptors Proteins 0.000 claims 1
- 108090000681 interleukin 20 Proteins 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000030173 low grade glioma Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 108010046239 paclitaxel-Angiopep-2 conjugate Proteins 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 108010043655 penetratin Proteins 0.000 claims 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims 1
- 108010076042 phenomycin Proteins 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 239000004308 thiabendazole Substances 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000005909 tumor killing Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022176907A JP2023022036A (ja) | 2016-12-09 | 2022-11-04 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| JP2025064400A JP2025118630A (ja) | 2016-12-09 | 2025-04-09 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432503P | 2016-12-09 | 2016-12-09 | |
| US62/432,503 | 2016-12-09 | ||
| PCT/US2017/065366 WO2018107058A1 (en) | 2016-12-09 | 2017-12-08 | Anti-sirp-alpha antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176907A Division JP2023022036A (ja) | 2016-12-09 | 2022-11-04 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500540A JP2020500540A (ja) | 2020-01-16 |
| JP2020500540A5 true JP2020500540A5 (enExample) | 2021-01-21 |
| JP7173971B2 JP7173971B2 (ja) | 2022-11-16 |
Family
ID=60888664
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530735A Active JP7173971B2 (ja) | 2016-12-09 | 2017-12-08 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| JP2022176907A Pending JP2023022036A (ja) | 2016-12-09 | 2022-11-04 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| JP2025064400A Withdrawn JP2025118630A (ja) | 2016-12-09 | 2025-04-09 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176907A Pending JP2023022036A (ja) | 2016-12-09 | 2022-11-04 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| JP2025064400A Withdrawn JP2025118630A (ja) | 2016-12-09 | 2025-04-09 | 抗ＳＩＲＰ－α抗体及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11779642B2 (enExample) |
| EP (1) | EP3551661A1 (enExample) |
| JP (3) | JP7173971B2 (enExample) |
| KR (2) | KR102650524B1 (enExample) |
| CN (2) | CN110325549B (enExample) |
| AU (2) | AU2017371070B2 (enExample) |
| CA (1) | CA3044684A1 (enExample) |
| SG (1) | SG10201912879YA (enExample) |
| WO (1) | WO2018107058A1 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN106350533B (zh) * | 2015-10-09 | 2020-07-17 | 上海宇研生物技术有限公司 | Anti-PD-L1-CAR-T及其制备方法和应用 |
| DK3443010T3 (da) | 2016-04-14 | 2024-09-30 | Ose Immunotherapeutics | Nye anti-SIRPa-antistoffer og terapeutiske anvendelser deraf |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| AU2018252193B2 (en) | 2017-04-14 | 2024-12-12 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| AU2018312222B2 (en) | 2017-08-02 | 2024-11-21 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| PE20210342A1 (es) | 2018-05-25 | 2021-02-23 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos |
| CN108872569A (zh) * | 2018-06-19 | 2018-11-23 | 浠思（上海）生物技术有限公司 | 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法 |
| CN112673023B (zh) * | 2018-07-10 | 2023-09-12 | 国立大学法人神户大学 | 抗SIRPα抗体 |
| CN108913721A (zh) * | 2018-07-23 | 2018-11-30 | 安徽古生物科技有限公司 | 表达cd40抗体的慢病毒载体、car-t细胞的构建方法及应用 |
| WO2020047651A1 (en) | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| CN111253486B (zh) * | 2018-09-27 | 2023-09-29 | 再鼎医药(上海)有限公司 | 抗pd-1抗体及其用途 |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| BR112021009275A2 (pt) | 2018-11-15 | 2022-01-04 | Byondis Bv | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. |
| EP3886915A4 (en) * | 2018-11-29 | 2022-10-19 | PF Argentum IP Holdings LLC | BIOMARKERS FOR CD47 BLOCKING THERAPY |
| WO2020180811A1 (en) * | 2019-03-04 | 2020-09-10 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| WO2021011678A1 (en) * | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| MX2022001321A (es) * | 2019-08-02 | 2022-05-20 | Akeso Pharmaceuticals Inc | Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo. |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| JP2022548484A (ja) * | 2019-09-16 | 2022-11-21 | サーフィス オンコロジー インコーポレイテッド | 抗ｃｄ３９抗体の組成物及び方法 |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| CN110734897A (zh) * | 2019-10-31 | 2020-01-31 | 浙江蓝盾药业有限公司 | 杂交瘤细胞株12g6、抗体及其应用 |
| JP7713447B2 (ja) | 2019-11-27 | 2025-07-25 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための組み合わせ療法 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| UA130121C2 (uk) * | 2019-12-24 | 2025-11-19 | Ланова Медісінс Лімітед | АНТИТІЛО ДО SIRP<font face="Symbol">a</font> |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| CN111635458A (zh) * | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
| CN115768796A (zh) * | 2020-05-08 | 2023-03-07 | 依勒克拉疗法公司 | SIRPα、SIRPβ1及SIRPγ抗体及其用途 |
| CA3178157A1 (en) | 2020-06-01 | 2021-12-09 | Jaume Pons | Combination therapies comprising a hypomethylation agent for treating cancer |
| CN114349867B (zh) * | 2020-10-14 | 2024-05-28 | 广东菲鹏制药股份有限公司 | 融合蛋白及其应用 |
| MX2023005201A (es) | 2020-11-04 | 2023-06-28 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas. |
| JP7663265B2 (ja) * | 2020-11-30 | 2025-04-16 | クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド | 抗ＳＩＲＰα抗体またはその抗原結合断片および適用 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4337268A4 (en) | 2021-05-11 | 2025-06-04 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| EP4347653A1 (en) | 2021-06-04 | 2024-04-10 | Boehringer Ingelheim International GmbH | Anti-sirp-alpha antibodies |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| IL309405A (en) | 2021-06-29 | 2024-02-01 | Seagen Inc | Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist |
| EP4376952A1 (en) * | 2021-07-30 | 2024-06-05 | Alector LLC | Anti-sirp-alpha antibodies and methods of use thereof |
| CN113846122B (zh) * | 2021-08-16 | 2023-08-25 | 中国医学科学院医学生物学研究所 | 一种过表达snca的腺相关病毒载体aav-snca、制备方法及其应用 |
| WO2023020459A1 (zh) * | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422752A1 (en) * | 2021-10-28 | 2024-09-04 | Baylor College of Medicine | Targeting neuronal sirpa for treatment and prevention of neurological disorders |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN117209604B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| KR20250006831A (ko) * | 2022-04-20 | 2025-01-13 | 바이오션, 인코포레이티드 | SIRPα를 표적화하는 항체 및 이의 용도 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN119213034A (zh) | 2022-05-17 | 2024-12-27 | 苏州创胜医药集团有限公司 | 双功能蛋白质及其制剂和用途 |
| IL316971A (en) | 2022-06-01 | 2025-01-01 | Alx Oncology Inc | Combination therapies for the treatment of urinary tract carcinoma |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences Inc | CD73 COMPOUNDS |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| JP2025537826A (ja) * | 2022-11-16 | 2025-11-20 | ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー | 抗ｓｉｒｐａ抗体についての効力予測バイオマーカー |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN116284354B (zh) * | 2022-12-26 | 2024-01-30 | 上海迈科康生物科技有限公司 | 检测重组人轮状病毒vp8抗原（vp8 p[4]）的单克隆抗体及其应用 |
| WO2024178354A2 (en) * | 2023-02-24 | 2024-08-29 | The Children's Hospital Of Philadelphia | Improved phox2b pc-car generation based on structure and saturation mutagenesis |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025097011A2 (en) * | 2023-11-01 | 2025-05-08 | Board Of Regents, The University Of Texas System | Therapies for treatment of myeloid malignancies |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| AU1701001A (en) | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
| US20020090674A1 (en) | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US7282556B2 (en) | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN101970478A (zh) | 2007-10-11 | 2011-02-09 | 大学健康网络 | 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物 |
| PT4160212T (pt) | 2008-01-15 | 2024-06-25 | Univ Leland Stanford Junior | Marcadores de células estaminais de leucemia mielóide aguda |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| PL2429574T3 (pl) | 2009-05-15 | 2015-12-31 | Univ Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie SIRP-CD47 |
| US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| AU2013343099A1 (en) | 2012-11-09 | 2015-05-14 | Pfizer Inc. | Platelet-derived growth factor B specific antibodies and compositions and uses thereof |
| PL4119153T3 (pl) | 2013-02-05 | 2024-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Terapie ukierunkowane na cd47 w leczeniu choroby zakaźnej |
| KR102276974B1 (ko) | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
| JP6606505B2 (ja) | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 |
| JP6517240B2 (ja) | 2014-05-22 | 2019-05-22 | シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． | 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ |
| SG11201700901SA (en) | 2014-08-08 | 2017-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| WO2016205042A1 (en) | 2015-06-16 | 2016-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα AGONIST ANTIBODY |
| EP4592391A3 (en) | 2015-10-21 | 2025-10-08 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| EP3995139A1 (en) | 2016-04-10 | 2022-05-11 | Georgia State University Research Foundation, Inc. | Composition for use in treating cancer |
| SG11201808465UA (en) | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| US11649284B2 (en) | 2016-04-18 | 2023-05-16 | Baylor College Of Medicine | Cancer gene therapy targeting CD47 |
| WO2017197495A1 (en) | 2016-05-19 | 2017-11-23 | Adaerata, Limited Partnership | Methods of preventing or treating slamf7 positive and slamf7 negative cancers |
| WO2018013534A1 (en) | 2016-07-11 | 2018-01-18 | Dana-Farber Cancer Institute, Inc. | Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
| US11274159B2 (en) | 2017-05-16 | 2022-03-15 | Byondis B.V. | Anti-SIRPα antibodies |
| PL3658141T3 (pl) | 2017-07-24 | 2023-06-12 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 |
| ES2963157T3 (es) | 2017-07-26 | 2024-03-25 | Forty Seven Inc | Anticuerpos anti-SIRP-alfa y métodos relacionados |
| CN112105646A (zh) | 2018-03-13 | 2020-12-18 | Ose免疫疗法 | 抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法 |
| PE20210342A1 (es) * | 2018-05-25 | 2021-02-23 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| BR112021009275A2 (pt) | 2018-11-15 | 2022-01-04 | Byondis Bv | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. |
| KR20210107062A (ko) | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 이작용성 항-PD-1/SIRPα 분자 |
-
2017
- 2017-12-08 JP JP2019530735A patent/JP7173971B2/ja active Active
- 2017-12-08 EP EP17822895.3A patent/EP3551661A1/en active Pending
- 2017-12-08 WO PCT/US2017/065366 patent/WO2018107058A1/en not_active Ceased
- 2017-12-08 AU AU2017371070A patent/AU2017371070B2/en active Active
- 2017-12-08 KR KR1020197019398A patent/KR102650524B1/ko active Active
- 2017-12-08 CN CN201780085877.7A patent/CN110325549B/zh active Active
- 2017-12-08 KR KR1020247009198A patent/KR20240039236A/ko not_active Withdrawn
- 2017-12-08 US US16/463,062 patent/US11779642B2/en active Active
- 2017-12-08 SG SG10201912879YA patent/SG10201912879YA/en unknown
- 2017-12-08 CN CN202410149645.5A patent/CN118027200A/zh active Pending
- 2017-12-08 CA CA3044684A patent/CA3044684A1/en active Pending
-
2022
- 2022-11-04 JP JP2022176907A patent/JP2023022036A/ja active Pending
-
2023
- 2023-08-23 US US18/454,286 patent/US12226482B2/en active Active
-
2025
- 2025-01-09 US US19/014,653 patent/US20250144209A1/en active Pending
- 2025-03-12 AU AU2025201767A patent/AU2025201767A1/en active Pending
- 2025-04-09 JP JP2025064400A patent/JP2025118630A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023022036A5 (enExample) | ||
| JP2020500540A5 (enExample) | ||
| JP2018518176A5 (enExample) | ||
| JP2018525999A5 (enExample) | ||
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2018518491A5 (enExample) | ||
| JP7132232B2 (ja) | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 | |
| JP2024119791A5 (enExample) | ||
| JPWO2019226973A5 (enExample) | ||
| JP7320944B2 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2019500892A5 (enExample) | ||
| US20170198038A1 (en) | MULTISPECIFIC NKp46 BINDING PROTEINS | |
| KR20180034588A (ko) | Pd-1-결합 분자 및 그것의 사용 방법 | |
| JP2019521645A5 (enExample) | ||
| JP2019500891A5 (enExample) | ||
| JP2019517539A (ja) | 併用療法 | |
| JP2019509055A5 (enExample) | ||
| KR20180021786A (ko) | Lag-3-결합 분자 및 그 사용 방법 | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| CN110312525A (zh) | T细胞重定向多功能抗体与免疫检查点调节剂的组合及其用途 | |
| CA3057139A1 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| KR20240042009A (ko) | 항-cd38 항체, 항-cd3 항체, 및 이중특이적 항체 및 이의 용도. | |
| Du et al. | Engineered bifunctional proteins for targeted cancer therapy: prospects and challenges | |
| JPWO2019195452A5 (enExample) |